Famciclovir is an antiviral with efficacy and safety comparable to aciclovir, but famciclovir's more favorable pharmacokinetic profile enables a less frequent dosing regimen. Future trials will likely determine famciclovir's role in the suppression of HBV. Infect. Dis. Obstet. Gynecol, 5:3-7, 1997. (C) 
currently approved dosing regimen of famciclovir for the treatment of herpes zoster (shingles) is 500 mg rid for 7 days; for recurrent genital herpes it is 125 mg bid for 5 days. This treatment is also effective for treatment of first episode genital herpes at a dose of 250 mg rid for 5 days and chronic suppression of recurrences at a dose of 250 mg bid.
However, the last two indications are still pending approval by U.S. regulatory authorities.
STRUCTURE AND DERIVATION
Famciclovir (2-[2-(2-amino-9H-purin-9-yl)ethyl]-1,3-propanediol diacetate) is the diacetyl ester of 6-deoxy penciclovir (a synthetic acyclic guanine derivative). Whereas penciclovir itself is very poorly absorbed orally, it was found in animal studies that its dipropionyl and diacetyl 6-deoxy derivatives (BRL 43599 and famciclovir, respectively) gave much improved blood levels of penciclovir. Furthermore 6 Unlike aciclovir, which has a 10-20% bioavailability, 7 the bioavailability of penciclovir after oral administration of famciclovir is about 77%. 4, 8, 9 Compared to aciclovir, penciclovir is preferentially taken up and phosphorylated by HSV-and VZV-infected cells. Furthermore, penciclovir triphosphate has a very prolonged intracellular half-life in infected cells (7 to 20 hours versus 0.7 to hour for aciclovir triphosphate), z Penciclovir is not metabolized but is eliminated unchanged in the urine. 1 The pharmacokinetics of penciclovir remain largely unaltered in the elderly, making it unnecessary to adjust the dosage in these patients. TM In a study of patients with renal impairment, urinary excretion of pcnciclovir decreased in proportion to the decrease in estimated creatine clearance leading to a recommendation that the dosage interval of famciclovir should be prolonged from 8 hours to 12 hours for patients with moderate renal impairment, and to 24 hours for patients with severe renal impairment. 13 There is no evidence for the need to alter dosage levels of famciclovir in those with well-compensated hepatic impairmerit. 4 The pharmacokinetics of famciclovir have not been studied in patients with severe uncompensated hepatic impairment.
In three studies that investigated the effects of food on the pharmacokinetics and bioavailability of famciclovir,S-17 no clinically significant differences were observed in healthy male volunteers who received famciclovir (250 and 500 mg single doses) 30 To determine the efficacy and safety of famciclovir in the episodic treatment of recurrent genital herpes, a multicenter, randomized, double-blind, dose-ranging, patient-initiated study was conducted comparing three twice-daily doses (125, 250, and 500 mg) of oral famciclovir with placebo over a 5-day period. 18 Famciclovir at all doses was significantly more effective than placebo at 'reducing time to healing, time to cessation of viral shedding, as well as durations of lesion edema, vesicles, ulcer, and crusts. Times to cessation of all symptoms and of moderate to severe lesion tenderness, pain, and burning were also reduced. Patients who initiated famciclovir prior to viral shedding more frequently aborted the onset of viral shedding. All doses were equally effective and well tolerated.
A similar multicentre, clinic-initiated trial using oral famciclovir at the same three doses again demonstrated reductions of viral shedding, lesion discomfort, lesion duration, and new lesion formation in famciclovir-treated (all doses) patients, zs Lesion tenderness, itching, edema, and ulcer duration were also significantly reduced, and culture positive new lesions were more frequently avoided.
Recent trials have also shown favourable results with famciclovir for both the treatment of first episode genital herpes and for the suppression of recurrent genital herpes, z6 although these are not currently licensed indications in North America. Optimal dosing of famciclovir for first episodes was 250 mg tid, while for suppression, optimal dosing was 250 mg bid, and while for suppression, optimal dosing was 250 mg bid. z7 In a double-blind, placebo-controlled pilot study of 17 patients with chronic HBV infection, famciclovir (250 mg or 500 mg three times daily) 
